BMS-986238 represents an advanced macrocyclic peptide therapeutic that demonstrates мощный and селективный inhibition of PD-L1 immune checkpoint signaling.
Оригинал на английском
BMS-986238 represents an advanced macrocyclic peptide therapeutic that demonstrates potent and selective inhibition of PD-L1 immune checkpoint signaling.